Hexima Ltd · ASX:HXL
Hexima — Shareholder Meeting (November 2011)
17 slides from Hexima's shareholder meeting presentation, November 2011
Slide 1: Annual General Meeting November 2011 CSO report
Annual General Meeting November 2011 CSO report – Prof. Marilyn Anderson 1
Slide 2: Major projects
Major projects Disease control – corn, soybean, wheat Insect control MGEV - multigene expression vehicle for gene stacking in biotech crops Pharmaceutical applications 2
Slide 3: Why corn and soybean?
Why corn and soybean? Corn and soybean are the largest biotech crops globally (2010) Biotech crop Global biotech area Global value Soybean 50% 73.3mHa US$4.3b Corn 31% 46.8mHa US$5.4b Cotton 14% 21.0mHa US$1.2b Cotton 5% 7.0mHa US$0.3b The market for biotech crops has grown rapidly in the 15 yea
Slide 4: Why fungal diseases?
Why fungal diseases? Almost all of the current biotech crops have one of two traits Herbicide resistance for weed control Bt toxins for insect control Stacked products (for weed and insect control) are now a very important feature (41% of the USA market) Stacked products with new traits (i
Slide 5: Why fungal diseases?
Why fungal diseases? Fungal diseases are amongst the most serious threats to food security Pennisi (2010) Science, 327, 804 We are focusing on diseases in the major biotech crops Gibberella stalk rot Diplodia ear rot In corn annual yield losses from fungal diseases are about 10-12% and cost ab
Slide 6: Pioneer collaboration-disease resistant corn
Pioneer collaboration-disease resistant corn Production of transgenic corn with resistance to fungal diseases using genes encoding antifungal proteins (AFPs) Discovery Phase 1 Phase 2 Phase 3 Phase 4 Identify genes for improved Proof of concept. Large scale Trials of traits in elite Commercial-isa
Slide 7: Milestones - DuPont/Pioneer collaboration
Milestones - DuPont/Pioneer collaboration Resistance to fungal disease in corn DISCOVERY PHASE 1 PHASES 2-4 GENE DISCOVERY & OPTIMISATION TRAIT VALIDATION Gene discovery Gene Corn transformation & (AFP selection) optimisation for proof of concept Field trials etc corn in glasshouse Transfer seed to
Slide 8: Disease project- achievements to date: gene discovery and AFP selection
Disease project- achievements to date Gene discovery and AFP selection Several AFPs with broad spectrum activity against corn pathogens have been identified Promising leads have been progressed to the corn transformation pipeline High throughput screening is continuing for identification of
Slide 9: Disease project- achievements to date: corn transformation
Disease project- achievements to date Corn transformation Genes encoding AFPs have been optimised and transferred into corn Corn transformation facility is operating at full capacity 9
Slide 10: Disease project- achievements to date: assessment of transgenic plants
Disease project- achievements to date Assessment of transgenic plants Good expression of AFPs in transgenic corn plants with no adverse affects Bioassays to assess efficacy for disease control are running at full capacity 10
Slide 11: Soybeans
Soybeans Last month Hexima announced that the Company and Pioneer had formally commenced the soybean disease program This program is targeting several diseases that are closely related to our target corn diseases Pioneer is undertaking all soybean transformation in their US facilities and sign
Slide 12: Leveraging our technology - wheat
Leveraging our technology - wheat Today Hexima announces a major new agreement with Monsanto to develop disease resistant wheat Monsanto has taken a research license and commercial option over Hexima’s AFPs Monsanto will build upon Hexima’s early work which has demonstrated efficacy against im
Slide 13: Intellectual Property
INTELLECTUAL PROPERTY Number of Applications & Granted Patents (Cumulative) 160 140 120 100 + 2006/07 2007/08 2008/09 2009/10 2010/11 BApplications Granted Patents
Slide 14: Intellectual Property- new patent applications
Intellectual Property- new patent applications Agricultural Anti Pathogenic Agents – US Provisional Patent Application filed on 7 February 2011 Pharmaceutical Applications Treatment of Proliferative Diseases – US Complete Patent Application filed on 26 June 2011 – International PCT Patent Ap
Slide 15: Hexima research
Hexima research Hexima research has been based at The University of Melbourne and La Trobe University Gene discovery – Professor Marilyn Anderson Product development – Dr Robyn Heath Pharmaceutical – Dr Mark Hulett Mark, Robyn & Marilyn 15
Slide 16: Consolidation of all teams at La Trobe
Consolidation of all teams at La Trobe In 2012, the U. Melb team will move to La Trobe University Research laboratories will be housed in the La Trobe Institute of Molecular Science 16
Slide 17: Thank you to our scientific teams
Thank you to our scientific teams Gene discovery - Marilyn Anderson Product development - Robyn Heath Pharmaceutical - Mark Hulett Intellectual property - Susanna Herd 17